Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer.

Trial Profile

Assessment of the efficacy and safety of zoledronic acid in the treatment of bone metastases-related pain in patients with prostate cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TRAPEZE
  • Sponsors Novartis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Dec 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top